Date | Debt to Equity Ratio | Debt to Income Ratio | Debt to Tangible Net Worth Ratio | Dividend Coverage Ratio |
---|
CEO | Mr. Kedarmal Shankarlal Bankda M.Com |
IPO Date | Nov. 18, 2022 |
Location | India |
Headquarters | 207, Saket Nagar |
Employees | 998 |
Sector | Healthcare |
Industries |
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It offers various products, including generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also provides histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, stimulants, and sympathomimetic products, as well as products used in the treatment of gout. In addition, it engages in the trading of commodities and renting of properties. Further, the company exports its products. It offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and herbals. Syncom Formulations (India) Limited was founded in 1985 and is based in Indore, India.
Past 5 years
USD 0.04
USD 0.53
USD 0.11
USD 4.51
USD 2.64
StockViz Staff
February 12, 2025
Any question? Send us an email